Biogen Idec and Eisai Announce Manufacturing Alliance at Research Triangle Park Facilities

  Biogen Idec and Eisai Announce Manufacturing Alliance at Research Triangle
  Park Facilities

  -- Deal Leverages Complementary Strengths for Both Research Triangle Park
                                 Employers --

    -- Reinforces Local Presence through Increased Capacity Utilization --

Business Wire

RESEARCH TRIANGLE PARK, N.C. -- December 12, 2012

Biogen Idec (NASDAQ: BIIB) and Eisai Inc. today announced a strategic alliance
that will bolster the manufacturing capabilities of both companies’ Research
Triangle Park (RTP)-based facilities. Under the terms of the agreement, Biogen
Idec will lease a portion of the Eisai facility to manufacture oral solid dose
products for both companies. Eisai will provide Biogen Idec with vial-filling
services for biologic therapies and packaging services for oral solid dose
products. The 10-year lease agreement gives Biogen Idec the option to purchase
the Eisai oral solid dose facility.

“We view our supply chain as a lifeline to patients, designed to deliver
quality therapies wherever and whenever they are needed,” said John G. Cox,
executive vice president of Pharmaceutical Operations and Technology, for
Biogen Idec. “This innovative capacity-sharing relationship with Eisai fits
strategically in our global drug supply network, particularly as we advance
our oral therapeutics.”

Approximately 50 Eisai personnel are expected to become Biogen Idec employees
in early 2013, building on the company’s RTP workforce which exceeded 1,000 in
2012. Eisai currently employs approximately 225 full-time employees at its RTP
site.

"We look forward to collaborating with Biogen Idec to continue the proud
history of drug manufacturing excellence here at our RTP site," said Lou Arp,
general manager of the Eisai RTP site and president of Global Oncology
Manufacturing, for Eisai Inc. "Our alliance will enable both companies to
focus on respective areas of expertise while continuing to deliver
high-quality and innovative products to patients. Moreover, employees will
benefit by working in a highly collaborative environment that offers
opportunities to further cultivate their careers.”

Biogen Idec and Eisai have both operated manufacturing facilities in RTP since
the mid-1990s. “This alliance underscores the Triangle region’s reputation as
a globally competitive location for life sciences,” said Bob Geolas, president
and CEO of the Research Triangle Foundation. “In addition, it’s an
illustration of the type of collaboration we encourage and foresee becoming
more commonplace as the Park moves forward with its new Master Plan.”

About Biogen Idec

Through cutting-edge science and medicine, Biogen Idec discovers, develops and
delivers to patients worldwide innovative therapies for the treatment of
neurodegenerative diseases, hemophilia and autoimmune disorders. Founded in
1978, Biogen Idec is the world’s oldest independent biotechnology company.
Patients worldwide benefit from its leading multiple sclerosis therapies, and
the company generates more than $5 billion in annual revenues. For product
labeling, press releases and additional information about the company, please
visit www.biogenidec.com.

About Eisai Inc.

Eisai Inc. was established in 1995 and began marketing its first product in
the United States in 1997. Since that time, Eisai Inc. has rapidly grown to
become a fully integrated pharmaceutical business. Eisai's key areas of
commercial focus are neurology and oncology. The company serves as the U.S.
pharmaceutical operation of Eisai Co., Ltd., a research-based human health
care (hhc) company that discovers, develops and markets products throughout
the world. Eisai has a global product creation organization that includes
U.S.-based R&D facilities in Massachusetts, New Jersey, North Carolina and
Pennsylvania, as well as manufacturing facilities in Maryland and North
Carolina. The company's areas of R&D focus include neuroscience; oncology;
vascular, inflammatory and immunological reaction; and antibody-based
programs. For more information about Eisai, please visit www.eisai.com/US.

Contact:

Biogen Idec Media Contact:
Mike McBrierty, 919-993-6368
Senior Manager, Public Affairs
or
Biogen Idec Investor Contact:
Benjamin Strain, 781-464-2442
Senior Manager, Investor Relations
or
Eisai Inc. Media Contact:
Lynn Kenney, 201-746-2294
Senior Director, Corporate Communications
or
Eisai Inc. Investor Contact:
Alex Scott, 201-746-2177
Vice President, Commercial Development
 
Press spacebar to pause and continue. Press esc to stop.